Virginia Stauffer

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. doi request reprint Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials
    Virginia Stauffer
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Res 130:11-9. 2011
  2. doi request reprint Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms
    Virginia L Stauffer
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Res 134:195-201. 2012
  3. pmc Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis
    Virginia L Stauffer
    Neuroscience, Lilly USA, LLC, Indianapolis, IN 46285, USA
    BMC Psychiatry 9:12. 2009
  4. pmc Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials
    Virginia Stauffer
    Lilly Research Laboratories, Indianapolis, IN, USA
    BMC Psychiatry 9:13. 2009
  5. pmc Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial
    Douglas Faries
    Eli Lilly and Company, Lilly Corporate Center, DC 5024, Indianapolis, IN 46285, USA
    BMC Med Res Methodol 12:142. 2012
  6. doi request reprint Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study
    Bruce J Kinon
    Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 28:392-400. 2008
  7. doi request reprint Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods
    Lei Chen
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA
    Schizophr Res 113:34-40. 2009
  8. pmc Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
    Stephen J Ruberg
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 11:23. 2011
  9. pmc The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial
    Lei Chen
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 13:320. 2013
  10. doi request reprint Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited
    Haya Ascher-Svanum
    Eli Lilly and Co, Indianapolis, IN
    Clin Schizophr Relat Psychoses 8:84-90, 90A. 2014

Detail Information

Publications13

  1. doi request reprint Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials
    Virginia Stauffer
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Res 130:11-9. 2011
    ..Most patients had modest and sustained improvements during atypical antipsychotic treatment, regardless of their baseline illness severity, representing a partial response to currently available treatments...
  2. doi request reprint Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms
    Virginia L Stauffer
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Res 134:195-201. 2012
    ..This distinction, incorporating an evaluation of the presence of positive, affective, and extrapyramidal symptoms, may therefore not have prognostic implications for the responsiveness of patients' negative symptoms to treatment...
  3. pmc Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis
    Virginia L Stauffer
    Neuroscience, Lilly USA, LLC, Indianapolis, IN 46285, USA
    BMC Psychiatry 9:12. 2009
    ..Identification of patient subgroups with different degrees of susceptibility to the effect of weight mitigating agents during olanzapine treatment may aid clinicians in treatment decisions...
  4. pmc Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials
    Virginia Stauffer
    Lilly Research Laboratories, Indianapolis, IN, USA
    BMC Psychiatry 9:13. 2009
    ..This post-hoc analysis describes maintenance of response over 24 or 28 weeks in people treated for schizophrenia with olanzapine, risperidone, quetiapine, ziprasidone, or aripiprazole...
  5. pmc Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial
    Douglas Faries
    Eli Lilly and Company, Lilly Corporate Center, DC 5024, Indianapolis, IN 46285, USA
    BMC Med Res Methodol 12:142. 2012
    ....
  6. doi request reprint Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study
    Bruce J Kinon
    Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 28:392-400. 2008
    ....
  7. doi request reprint Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods
    Lei Chen
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA
    Schizophr Res 113:34-40. 2009
    ..Identify the optimal magnitude of response to antipsychotic medication at various early time points that best predicts subsequent non-response at 8 weeks...
  8. pmc Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
    Stephen J Ruberg
    Eli Lilly and Company, Indianapolis, IN, USA
    BMC Psychiatry 11:23. 2011
    ..To identify a simple decision tree using early symptom change to predict response to atypical antipsychotic therapy in patients with (Diagnostic and Statistical Manual, Fourth Edition, Text Revised) chronic schizophrenia...
  9. pmc The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial
    Lei Chen
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 13:320. 2013
    ..This study assessed the temporal interplay between these two symptom domains and evaluated whether the improvements in these symptoms were inversely correlated or independent with each other...
  10. doi request reprint Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited
    Haya Ascher-Svanum
    Eli Lilly and Co, Indianapolis, IN
    Clin Schizophr Relat Psychoses 8:84-90, 90A. 2014
    ..We assessed whether a patient's perception of medication benefit early in treatment could predict subsequent response or nonresponse to continued use of the same treatment...
  11. ncbi request reprint Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    Prog Neuropsychopharmacol Biol Psychiatry 28:985-96. 2004
    ..The aim of this 8-month study was to determine if olanzapine treatment could lead to a significant and persistent reduction in preexisting TD...
  12. doi request reprint Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 26:2403-10. 2010
    ..To identify reasons for discontinuation and continuation of antipsychotic medications in the treatment of schizophrenia from the patients' and their clinicians' perspectives...
  13. doi request reprint Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics
    Bruce J Kinon
    Eli Lilly and Company, Indianapolis, IN, USA
    J Geriatr Psychiatry Neurol 28:67-79. 2015
    ..The risk of persistent tardive dyskinesia (TD) was compared in patients with acute psychosis or agitation aged 55 years or older who were treated with olanzapine (OLZ) or conventional antipsychotic (CNV) drug therapy...